58 related articles for article (PubMed ID: 32816149)
1. Exploring conformational changes of PPAR-Ɣ complexed with novel kaempferol, quercetin, and resveratrol derivatives to understand binding mode assessment: a small-molecule checkmate to cancer therapy.
Lokhande KB; Ballav S; Thosar N; Swamy KV; Basu S
J Mol Model; 2020 Aug; 26(9):242. PubMed ID: 32816149
[TBL] [Abstract][Full Text] [Related]
2. Exploring binding mode assessment of novel kaempferol, resveratrol, and quercetin derivatives with PPAR-α as potent drug candidates against cancer.
Ballav S; Lokhande KB; Yadav RS; Ghosh P; Swamy KV; Basu S
Mol Divers; 2023 Dec; 27(6):2867-2885. PubMed ID: 36544031
[TBL] [Abstract][Full Text] [Related]
3. Uncovering PPAR-γ agonists: An integrated computational approach driven by machine learning.
Haider S; Shafiq M; Siddiqui AR; Sardar M; Mushtaq M; Shafeeq S; Nur-E-Alam M; Ahmad A; Ul-Haq Z
J Mol Graph Model; 2024 Jun; 129():108742. PubMed ID: 38422823
[TBL] [Abstract][Full Text] [Related]
4. Virtual screening, pharmacokinetics & MD simulation study of active phytoconstituents of
Deshpande N S; Dwivedi PSR; Revanasiddappa BC
J Biomol Struct Dyn; 2023 Nov; ():1-17. PubMed ID: 37948295
[No Abstract] [Full Text] [Related]
5. Design, Synthesis, and Biological Evaluation of Novel Quercetin Derivatives as PPAR-γ Partial Agonists by Modulating Epithelial-Mesenchymal Transition in Lung Cancer Metastasis.
Ballav S; Bhosale M; Lokhande KB; Paul MK; Padhye S; Swamy KV; Ranjan A; Basu S
Adv Biol (Weinh); 2023 Oct; 7(10):e2300036. PubMed ID: 37017501
[TBL] [Abstract][Full Text] [Related]
6. Citrus nutraceutical eriocitrin and its metabolites are partial agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a molecular docking and molecular dynamics study.
Gangadhariah M; Pardhi T; Ravilla J; Chandra S; Singh SA
J Biomol Struct Dyn; 2023; 41(21):11373-11393. PubMed ID: 36576222
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.
Lewis SN; Garcia Z; Hontecillas R; Bassaganya-Riera J; Bevan DR
J Comput Aided Mol Des; 2015 May; 29(5):421-39. PubMed ID: 25616366
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the Therapeutic Potential of Curcumin and Synthetic Derivatives: A Computational Approach to Anti-Obesity Treatments.
Moetlediwa MT; Jack BU; Mazibuko-Mbeje SE; Pheiffer C; Titinchi SJJ; Salifu EY; Ramharack P
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473849
[TBL] [Abstract][Full Text] [Related]
9. Flavonostilbenes natural hybrids from
Elsaman T; Ahmad I; Eltayib EM; Suliman Mohamed M; Yusuf O; Saeed M; Patel H; Mohamed MA
J Biomol Struct Dyn; 2024 Apr; 42(6):3249-3266. PubMed ID: 37261483
[TBL] [Abstract][Full Text] [Related]
10. Identification of phytochemicals as putative ligands for the targeted modulation of peroxisome proliferator-activated receptor α (PPARα) in animals.
Hassan FU; Rehman MS; Javed M; Ahmad K; Fatima I; Safdar M; Ashraf N; Nadeem A
J Biomol Struct Dyn; 2023 Oct; ():1-12. PubMed ID: 37837423
[TBL] [Abstract][Full Text] [Related]
11. New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy.
Jia Z; Sun Y; Yang G; Zhang A; Huang S; Heiney KM; Zhang Y
PPAR Res; 2014; 2014():818530. PubMed ID: 24624137
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Pancreatic α-amylase by Resveratrol Derivatives: Biological Activity and Molecular Modelling Evidence for Cooperativity between Viniferin Enantiomers.
Mattio LM; Marengo M; Parravicini C; Eberini I; Dallavalle S; Bonomi F; Iametti S; Pinto A
Molecules; 2019 Sep; 24(18):. PubMed ID: 31491840
[TBL] [Abstract][Full Text] [Related]
13. Development of novel thiazolidine-2,4-dione derivatives as PPAR-γ agonists through design, synthesis, computational docking, MD simulation, and comprehensive
Gowdru Srinivasa M; B C R; Prabhu A; Rani V; Ghate SD; Kumar B R P
RSC Med Chem; 2023 Nov; 14(11):2401-2416. PubMed ID: 37974963
[TBL] [Abstract][Full Text] [Related]
14. Prospective de novo drug design with deep interactome learning.
Atz K; Cotos L; Isert C; Håkansson M; Focht D; Hilleke M; Nippa DF; Iff M; Ledergerber J; Schiebroek CCG; Romeo V; Hiss JA; Merk D; Schneider P; Kuhn B; Grether U; Schneider G
Nat Commun; 2024 Apr; 15(1):3408. PubMed ID: 38649351
[TBL] [Abstract][Full Text] [Related]
15. PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.
Belfiore A; Genua M; Malaguarnera R
PPAR Res; 2009; 2009():830501. PubMed ID: 19609453
[TBL] [Abstract][Full Text] [Related]
16. Prediction of resveratrol target proteins: a bioinformatics analysis.
Lagunas-Rangel FA
J Biomol Struct Dyn; 2024; 42(2):1088-1097. PubMed ID: 37011009
[TBL] [Abstract][Full Text] [Related]
17. Molecular Modelling of Resveratrol Derivatives with SIRT1 for the Stimulation of Deacetylase Activity.
Zamani M; Mokarram P; Jamshidi M; Siri M; Ghasemi H
Curr Comput Aided Drug Des; 2023 Oct; ():. PubMed ID: 37842901
[TBL] [Abstract][Full Text] [Related]
18. In-vitro analysis of selective nutraceuticals binding to human transcription factors through computer aided molecular docking predictions.
Teimouri M; Junaid M; Saleem S; Khan A; Ali A
Bioinformation; 2016; 12(7):354-358. PubMed ID: 28246465
[TBL] [Abstract][Full Text] [Related]
19. Probing intermolecular interactions and binding stability of kaempferol, quercetin and resveratrol derivatives with PPAR-γ: docking, molecular dynamics and MM/GBSA approach to reveal potent PPAR- γ agonist against cancer.
Lokhande KB; Ballav S; Yadav RS; Swamy KV; Basu S
J Biomol Struct Dyn; 2022 Feb; 40(3):971-981. PubMed ID: 32954977
[TBL] [Abstract][Full Text] [Related]
20. Anticancer Effects of Fufang Yiliu Yin Formula on Colorectal Cancer Through Modulation of the PI3K/Akt Pathway and BCL-2 Family Proteins.
Dong B; Yang Z; Ju Q; Zhu S; Wang Y; Zou H; Sun C; Zhu C
Front Cell Dev Biol; 2020; 8():704. PubMed ID: 32850824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
